Skip to Main Content

Author Details

Suchit Jhunjhunwala
Genentech Inc.
2002
38
26
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37027981The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens.Semin Immunol2023
37487664Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming.J Immunother Cancer2023
37741832Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.Nat Commun2023
36418317Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.Nat Commun2022
32940337In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales.Brief Bioinform2021
33750922Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.Nat Rev Cancer2021
33936100An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.Front Immunol2021
34172722Molecular determinants of response to PD-L1 blockade across tumor types.Nat Commun2021
32391432Cancer neoantigens and immunogenicity: mutation position matters.Mol Cell Oncol2020
31940002Mutation position is an important determinant for predicting cancer neoantigens.J Exp Med2020
30943407Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation.Cell Rep2019
31745090Transposable element expression in tumors is associated with immune infiltration and increased antigenicity.Nat Commun2019
31511069Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.J Immunother Cancer2019
29229751SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.J Cell Biol2018
29867230Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Nat Med2018
30291359Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Nat Med2018
29443960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018
27928884Building proteomic tool boxes to monitor MHC class I and class II peptides.Proteomics2017
28478383Characterizing neoantigens for personalized cancer immunotherapy.Curr Opin Immunol2017
28781121Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure.Cancer Cell2017
27875550An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition.PLoS One2016
26384565Nuclear positioning rather than contraction controls ordered rearrangements of immunoglobulin loci.Nucleic Acids Res2016
25840969A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.Clin Cancer Res2015
24807215Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.Nat Commun2014
25428506Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.Nature2014
25315065MBASED: allele-specific expression detection in cancer tissues and cell lines.Genome Biol2014
25159915Diverse modes of genomic alteration in hepatocellular carcinoma.Genome Biol2014
22108827Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.Cancer Res2012
23033341Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.Genome Res2012
22267523The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.Genome Res2012
22432722Complementary proteomic tools for the dissection of apoptotic proteolysis events.J Proteome Res2012
21673316TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.Sci Signal2011
21868360miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer.Sci Signal2011
21903424Multilineage priming of enhancer repertoires precedes commitment to the B and myeloid cell lineages in hematopoietic progenitors.Immunity2011
20543837A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate.Nat Immunol2010
19665968Chromatin architecture and the generation of antigen receptor diversity.Cell2009
18423198The 3D structure of the immunoglobulin heavy-chain locus: implications for long-range genomic interactions.Cell2008
11928499Genome-wide pathway analysis and visualization using gene expression data.Pac Symp Biocomput2002
  • 1 - 38 of 38

Recommended Authors

International Research Center, A.C.Camargo Cancer Center
Career Start Year 2016
Number of shared co-authors 0
University of California San Diego
Career Start Year 2016
Number of shared co-authors 1
Washington University School of Medicine
Career Start Year 2016
Number of shared co-authors 0
Washington University in St Louis
Career Start Year 2015
Number of shared co-authors 0
BC Cancer Research Institute
Career Start Year 2014
Number of shared co-authors 1
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 0
University of Texas Southwestern Medical Center
Career Start Year 2014
Number of shared co-authors 2
Massachusetts Institute of Technology
Career Start Year 2013
Number of shared co-authors 1
Cancer Research Center of Lyon, UMR INSERM 2, CNRS 5286
Career Start Year 2010
Number of shared co-authors 0
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2010
Number of shared co-authors 0
Emory University School of Medicine
Career Start Year 2009
Number of shared co-authors 1
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 0
University of California San Diego
Career Start Year 2008
Number of shared co-authors 2
UNC School of Medicine, The University of North Carolina at Chapel Hill
Career Start Year 2008
Number of shared co-authors 1
UPMC Hillman Cancer Center
Career Start Year 2007
Number of shared co-authors 1
St Vincent's Hospital Melbourne
Career Start Year 2006
Number of shared co-authors 0
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2005
Number of shared co-authors 0
Stanford University
Career Start Year 2005
Number of shared co-authors 2
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 1
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 0
Washington University
Career Start Year 2003
Number of shared co-authors 1
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 3
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 2
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 1
Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine
Career Start Year 2001
Number of shared co-authors 1
Stanford Center for Biomedical Informatics Research, Stanford University
Career Start Year 1999
Number of shared co-authors 1
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 3
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 6
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Career Start Year 1974
Number of shared co-authors 5

Collaborators

Genentech Inc.
Co-authored papers 6
Co-authored papers 5
University of California
Co-authored papers 5
University of California san francisco
Co-authored papers 3
Department of Food Bioengineering, Jeju National University
Co-authored papers 3
Addenbrooke's Hospital, University of Cambridge
Co-authored papers 2
Genentech Inc.
Co-authored papers 2
University of California San Diego
Co-authored papers 2
2Sunnybrook Research Institute
Co-authored papers 2
Mayo Clinic Hospital
Co-authored papers 2
University of California San Diego
Co-authored papers 2
Co-authored papers 2
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Co-authored papers 2
Baylor Institute for Immunology Research
Co-authored papers 2
Michigan State University College of Human Medicine
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Data4Cure Inc.
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Center for Computational Biomedicine, Harvard Medical School
Co-authored papers 2
Lund University, Linkoping University. .
Co-authored papers 2
University of California
Co-authored papers 1
Memorial Sloan-Kettering Cancer Center
Co-authored papers 1
the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Co-authored papers 1
University of California San Diego
Co-authored papers 1
Genentech Inc.
Co-authored papers 1
Co-authored papers 1